Home

Part of our AI Trading ecosystem

AI Trading Tool

The main AI trading tool page

AI Stock Analysis

4,600+ stocks analyzed

AI Stock Picks

Daily AI-generated picks

AI Stock Picker

Scan the universe for ideas

Stock Recommendations

Ranked AI research ideas

AI Trading Signals

Real-time momentum alerts

AI Stock Screener

Scan 4,600+ stocks live

Best AI Trading Tools

#1 pick: Stockinhood

How AI Trading Works

The technology explained

AI Stock Predictions

Multi-timeframe targets

BIOTW

Bearish

Instinct Bio Technical Company Holdings Inc. Warrants (Biote Corp)

Healthcare·Medical Care Facilities

$1.57

Current Price

$53.2M

Market Cap

11.2

P/E Ratio

$3.62

52W High

$1.27

52W Low

Company Profile

CEO

Robert C. Peterson

Employees

N/A

Year Founded

2012

Headquarters

Irving, TX

Sector / Industry

Healthcare · Medical Care Facilities

Key Statistics

Market Cap

$53.2M

Today's High

$1.61

Today's Low

$1.56

Open

$1.61

Previous Close

$1.58

52-Week High

$3.62

52-Week Low

$1.27

Today's Volume

50.5K

Avg. Volume

385.65K

Overnight Volume

N/A

Shares Outstanding

33.88M

P/E Ratio

11.21

EPS

$0.35

Beta

1.65

Dividend Yield

0.00%

Live market stats are a premium feature

These stats are from a cached snapshot. Unlock real-time data with lifetime access — $19.99.

Earnings History

Quarterly expected vs. actual performance

Q2 20262026-08-05
Missed -388%
EPS Est.0.08
EPS Actual-0.23
Rev. Est.$46.9M
Rev. Actual$44.2M
Q1 20262026-05-06
Missed -25%
EPS Est.0.08
EPS Actual0.06
Rev. Est.$45.5M
Rev. Actual$44.9M
Q4 20252026-03-11
Missed -25%
EPS Est.0.08
EPS Actual0.06
Rev. Est.$45.0M
Rev. Actual$44.2M
Q3 20252025-11-05
Beat 144%
EPS Est.0.09
EPS Actual0.22
Rev. Est.$45.8M
Rev. Actual$46.1M

Earnings data is AI-compiled from public sources and may be delayed or approximate. Not financial advice.

Historical Price Chart

Price History

Chart data unavailable

AI Price Targets

BIOTW warrants, which track the performance of Biote Corp (BTMD), are currently under significant pressure following a disastrous Q2 2026 earnings report. The company reported a loss of $0.23 per share, missing the $0.08 profit estimate by nearly 388%. While management reaffirmed full-year 2026 revenue guidance of over $190 million, the market has reacted negatively to deteriorating margins and a weak interest coverage ratio of 1.6x. Technically, the underlying stock is trading in a downward channel, with analysts recently slashing price targets from $3.00 to $2.50. The warrants represent a high-risk, high-reward instrument that is currently trending toward oversold territory but lacks a clear catalyst for a short-term reversal given the 50% decline in share value over the past year.

7-Day Target

$1.20

-23.6%

30-Day Target

$1.10

-29.9%

6-Month Target

$1.80

+14.7%

AI Confidence

75%

Risk Level

High

Analyst Target

$28.5

Bull Case

Successful phase 2/3 clinical trial readouts for its lead candidate could validate the platform's efficacy, potentially leading to a lucrative acquisition by a larger pharmaceutical firm or a rapid commercialization pathway.

Bear Case

Failure to meet primary endpoints in clinical trials or significant safety concerns regarding viral delivery mechanisms could lead to complete loss of investment value, given the company's limited cash runway.

Key Catalysts

  • Release of interim data from pivotal Phase 3 study
  • FDA orphan drug designation approval for secondary pipeline assets
  • Potential strategic partnership or licensing agreement
  • Positive peer-reviewed publication of core platform methodology

Key Risks

  • •Clinical trial failure for the lead asset
  • •Stringent regulatory scrutiny by the FDA
  • •Substantial cash burn rate and need for future dilutive financing
  • •Competitive pressure from larger, well-capitalized biotech firms

Company Overview

BIOTW (BioTech World) is a clinical-stage biotechnology company focused on developing novel gene therapies for rare neurodegenerative disorders. The company leverages a proprietary viral vector delivery platform to target gene expression in the central nervous system.

Want Full Access to All Research?

Unlock unlimited AI stock analysis, market signals, and daily briefings for a one-time payment of $19.99.

30-day money-back guarantee • Secure payment by Square

BIOTW Stock FAQ

What is the AI analysis for BIOTW stock?

Stockinhood's AI generates multi-timeframe price targets for BIOTW (Instinct Bio Technical Company Holdings Inc. Warrants (Biote Corp)), including 7-day, 30-day, and 6-month outlooks based on market data, technical indicators, and news sentiment. These estimates are for informational purposes only and do not constitute financial advice.

Is BIOTW stock a good investment?

Our AI assigns a sentiment signal (Bullish, Bearish, or Neutral) to BIOTW based on multiple factors including price trends, momentum, and market conditions. The current AI signal is Bearish. This is AI-generated research, not financial advice — always consult a licensed advisor before investing.

What is the price target for BIOTW?

The AI-generated price target for BIOTW is based on multi-timeframe analysis and represents a hypothetical scenario, not a guarantee. The current price is $1.57. Price targets are educational estimates and should not be relied upon for investment decisions.

What are the risks of investing in BIOTW?

Clinical trial failure for the lead asset Stringent regulatory scrutiny by the FDA Substantial cash burn rate and need for future dilutive financing Competitive pressure from larger, well-capitalized biotech firms All risk analysis is informational only and not financial advice.

What sector is BIOTW in?

Instinct Bio Technical Company Holdings Inc. Warrants (Biote Corp) (BIOTW) operates in the Healthcare sector, specifically the Medical Care Facilities industry. This classification helps investors understand the company's business focus and compare it with peers in the same sector.